Table 3 Logistic regression analyses for clinicians’ adherence to ACCP guidelines
Variable | Adherent group | Non-adherent group | OR (Univariate) | OR (multivariate) |
|---|---|---|---|---|
Age (mean;SD) | 73.84 (1.04) | 73.89 (0.82) | 1.0 (95%CI 0.98–1.0; p = 0.97) | - |
Sex (%) | Female 35.75 | Female 37.93 | 0.91 (95%CI 0.57–1.45; p = 0.69) | - |
Male 64.25 | Male 62.07 | |||
CHA2DS2VASc (mean;SD) | 3.80 (0.13) | 3.90 (0.14) | 0.97 (95%CI 0.86–1.10; p = 0.62) | - |
Antiplatelet agent (%) | Yes (89.66), No (10.34) | Yes (86.88), No (13.12) | 0.76 (95%CI 0.37–1.56; p = 0.46) | - |
DOAC indication (AF vs VTE) (%) | AF (71.55) | AF (71.95) | 1.02 (95%CI 0.62–1.56; p = 0.94) | - |
VTE (28.45) | VTE (30.22) | |||
BMI (mean;SD) | 27.09 (0.46) | 26.09 (0.32) | 1.04 (95%CI 1.0–1.1; p = 0.07) | 1.05 (95%CI 0.99–1.1; p = 0.09) |
DOAC type (%) | Rivaroxaban (37.07) | Rivaroxaban (28.05) | - | - |
Edoxaban (8.62) | Edoxaban (9.50) | 0.69 (95%CI 0.29–1.60; p = 0.39) | 0.76 (95%CI 0.31–1.87; p = 0.55) | |
Apixaban (50.86) | Apixaban (58.37) | 0.65 (95%CI 0.40–1.08; p = 0.10) | 0.57 (95%CI 0.33–0.97; p = 0.04) | |
Dabigatran (3.45) | Dabigatran (4.07) | 0.64 (95%CI 0.19–2.22; p = 0.48) | 0.52 (95%CI 0.14–1.93; p = 0.33) | |
Bleeding risk (%) | High bleeding risk (59.48) | High bleeding risk (38.46) | - | - |
Low/moderate bleeding risk (26.72) | Low/moderate bleeding risk (29.41) | 0.59 (95%CI 0.34–1.00; p = 0.05) | 0.54 (95%CI 0.46–1.50; p = 0.67) | |
Minimal bleeding risk (13.79) | Minimal bleeding risk (3.21) | 0.27 (95%CI 0.15–0.52; p < 0.001) | 0.53 (95%CI 0.24–1.13; p = 0.1) | |
Type of anaesthesia (%) | General (83.62) | General (58.82) | - | - |
Neuraxial (4.31) | Neuraxial (4.52) | 0.67 (95%CI 0.22–2.02; p = 0.48) | 0.56 (95%CI 0.18–1.76; p = 0.32) | |
Local (11.21) | Local (35.29) | 0.22 (95%CI 0.12–0.43; p < 0.001) | 0.30 (95%CI 0.14–0.66; p < 0.01) | |
Other (0.86) | Other (1.36) | 0.45 (95%CI 0.05–4.36; p = 0.49) | 0.59 (95%CI 0.05–6.75; p = 0.67) |